A hyperpolarized 129 Xe contrast agent composed of many cryptophane-A molecular cages assembled on an M13 bacteriophage has been demonstrated. Saturation of xenon bound in the large number of cryptophane cages is transferred to the pool of aqueous-solvated xenon via chemical exchange, resulting in efficient generation of hyperCEST contrast. No significant loss of contrast per cryptophane cage was observed for the multivalent phage when compared with unscaffolded cryptophane. Detection of this phage-based hyperCEST agent is reported at concentrations as low as 230 fM, representing the current lower limit for NMR/MRIbased contrast agents.
INTRODUCTION
Molecular imaging aims to detect the presence and map the spatial distribution of tissue biomarkers that are of specific interest in biological systems under investigation. For many diseases such as cancer, early detection of the important biomarkers when they exist at very low concentrations maximizes the diagnostic and prognostic value. Because of MRI's inherent lack of signal sensitivity, it is difficult to generate contrast between normal and diseased tissue at these early disease stages with conventional imaging. Consequently, exogenous contrast agents are often used to generate unique contrast since many agents can be detected at lower concentrations than endogenous spins. The most common agents, principally gadolinium chelates (1), enhance water relaxation through paramagnetic interactions. Other types of agents that are being developed include paramagnetic shift reagents (e.g., anisotropic lanthanide chelates) enabling chemical exchange saturation transfer (CEST) contrast (2) , super-paramagnetic iron oxide field perturbation agents (3), and agents incorporating or composed of nonproton spin nuclei-both thermally polarized ( 19 F) (4) and hyperpolarized ( 13 C, 3 He, 129 Xe, 15 N, 19 F) (5-9). However, these MRI agents lack the sensitivity of positron emission tomography and single-photon emission computed tomography nuclear medicine techniques in which the radioactive tracers can be detected at subnanomolar concentrations (10) ; these lower detection thresholds better reflect the desired detection sensitivity for clinically relevant targeted molecular imaging applications.
Recently developed MRI contrast agents called xenon biosensors (11) have demonstrated the ability to utilize the complementary sensitivity enhancements of both hyperpolarized 129 Xe and CEST detection (12) . The resulting ''hyperCEST'' contrast mechanism has demonstrated detection thresholds of these biosensors that are several orders of magnitude lower than those of the previously mentioned MRI agents-down to 10 nM (13) . Xenon biosensors use cryptophane-A molecular cages (CryA) (14) to reversibly bind xenon atoms that have been dissolved into environments such as aqueous tissue. These constructs can also be functionalized with application specific targeting moieties (11, 12, (15) (16) (17) (18) (19) (20) (21) . The CryA bound xenon atoms (Xe@CryA) are in continuous exchange with the more abundant pool of solvated xenon nuclei that are diffusing in the surrounding aqueous environment (Xe@water). Because of the highly sensitive chemical shift response of 129 Xe to its local environment, two distinct resonance frequencies representing the Xe@CryA and Xe@water pools can be individually detected and manipulated at chemical shifts of approximately 60 ppm and 190 ppm downfield from the 129 Xe gas frequency, respectively. By applying saturating radiofrequency pulses at the 129 Xe@CryA frequency for a period that is long compared to the mean xenon residence time inside CryA (the inverse of the dissociation rate), the CEST mechanism allows a single biosensor molecule to saturate the magnetization of hundreds of 129 Xe@water nuclei. The complementarity of hyperpolarization and CEST arises from the fact that the bulk spin pool is typically made up of a low concentration of highly polarized 129 Xe@water spins to elicit significant contrast. Furthermore, the hyperCEST detection scheme can be used quickly relative to the long T 1 relaxation times of 129 Xe [approximately 6-10 s in oxygenated blood at 1.5 T (23,24) and 60 s in aqueous solvents at 4.7 T (25)] to minimize relaxation-based contrast loss. To improve the detection sensitivity of biologically targeted agents further, multiple copies of CryA have been assembled onto supramolecular scaffolds, such as branched dendrimers (26) and viral capsids (27) , which can then be further functionalized with targeting groups. This scaffolding approach has also been explored for PARACEST agents (28) .
In this work, the filamentous bacteriophage M13 was selected as an advantageous scaffold for molecular imaging development based on two principal criteria. First, filamentous phage such as the M13 and fd types are routinely used in phage display techniques for identifying new epitope targeting groups such as antibody fragments (29, 30) . Consequently, established phage display techniques can produce M13 phage that have high binding affinities for application-specific targets such as biomarkers of disease. Second, the single-stranded DNA of the M13 bacteriophage is coated with approximately 2700 identical copies of its major coat protein (p8), on which a large number of CryA cages can be covalently attached using site-specific protein bioconjugation techniques (31) (32) (33) . The result is an increase in CryA payload per targeted biomarker that is bound by the modified phage. Additionally, phage modification also presents an opportunity to decorate the CryA-bearing scaffold with polyethylene glycol (PEG), which can aid in the solubility and biocompatibility of the agent. The extent to which the hyperCEST-based contrast scales with the number of CryA cages per agent is dependent on several parameters, including changes in the xenon exchange dynamics and bound 129 Xe linewidths (due to slower molecular tumbling of the macromolecular scaffold), and thus must be investigated.
The purposes of this study were to investigate the feasibility of using M13 bacteriophage modified with CryA molecular cages as a hyperpolarized xenon MR contrast agent, to compare the hyperCEST response of this phagebased agent relative to unscaffolded CryA, and to establish an in vitro concentration threshold for detecting CryA-modified M13.
METHODS

Agent Preparation
To generate the CryA-modified M13, the protein capsid of the bacteriophage was site-selectively modified. Of the five coat proteins that surround the genetic material of M13 phage (illustrated in Fig. 1 ), the p8 protein is the most abundant with approximately 2700 copies. To functionalize the p8 protein, the M13 underwent a pyridoxal 5 0 -phosphate mediated biomimetic transamination reaction (65 nM M13 and 100 mM pyridoxal 5 0 -phosphate in 150 mM phosphate buffer, pH 6.3, for 18 h at 298 K) (34) to introduce ketone groups at the N-termini of these proteins (termed k-p8, Fig. 1 ). Further details of this reaction and characterization of the resulting phage have been reported elsewhere (unpublished data). This product (k-M13) was purified through a series of precipitations and resuspensions in Dulbecco's phosphate-buffered saline. To improve solubility and bioavailability of the construct, some of the ketone groups were reacted with aminooxy-functionalized 5 kDa PEG (PEG5kAONH 2 ) (35) (20 nM k-M13 and 20 mM PEG5kAONH 2 with 10 mM aniline in 150 mM phosphate buffer, pH 6.0, for 1 h at 293 K). Following gel filtration purification (illustra NAP-5 column, GE Healthcare), the PEG-modified M13 (M13-PEG) was reacted with an aminooxy-functionalized CryA-peptide (CryAAONH 2 ) (13 nM M13-PEG and 240 mM aminooxy CryA with 100 mM aniline in 150 mM phosphate buffer, pH 5.5, for 22 h at 293 K), modifying some of the remaining N-terminal ketone groups (Fig. 1) . The resulting M13-PEG-CryA conjugate, henceforth termed M13-based biosensor, was purified by gel filtration. Characterization and quantification of the intermediates and final products were performed using a combination of spectrophotometry (Nanodrop 2000, Thermo Fisher Scientific, MA), reverse phase-high performance liquid chromatography (RP-HPLC, 1100 Series, Agilent Technologies, CA) and electrospray ionization mass spectrometry (LTQ Orbitrap XL, Thermo Fisher Scientific). On average, the p8 coat proteins of the M13-based biosensor were approximately 28% modified with PEG-5k (760 copies) and approximately 39% modified with CryA (1050 copies) (Fig. 2) . While PEG-5k was required to ensure the aqueous solubility of the phage following the high level of modification with hydrophobic CryA, the level of PEG-5k modification was controlled to allow sufficient access to the ketone groups for the subsequent CryA attachment. Moreover, the CryA modification was controlled to balance the desire for high CryA payloads with the need for maintaining aqueous solubility. The construct was dissolved in filtered Dulbecco's phosphate-buffered saline (pH 7.4) for 129 Xe NMR testing. Control NMR experiments were performed with solutions containing unscaffolded CryA-peptide (i.e., CryAAONH 2 ) in Dulbecco's phosphate-buffered saline. Further details on the CryAAONH 2 synthesis and phage characterization are provided as an appendix.
NMR Experiments
A pressurized xenon gas mixture (2% natural abundance xenon, 10% nitrogen, and 88% helium at 584 kPa) was hyperpolarized to approximately 5% with a MITI XenoSpin spin exchange optical pumping polarizer (GE Healthcare, formerly Nycomed Amersham, Buckinghamshire, UK) and dissolved into 650 mL of biosensor solution by bubbling through a small capillary into a 5 mm NMR tube modified with a gas outflow elbow (Fig. 3 ). For every sample tested, a small amount (0.002% v/v) of a low hydrophilic-lipophilic balance surfactant (Pluronic F-68, BASF, Edison, NJ) was added to minimize foaming as well as potential stress on any proteins in solution during bubbling. Before each pulse sequence repetition, the xenon mixture was bubbled at a flow rate of approximately 0.05 SLM to saturate the solution with hyperpolarized 129 Xe, followed by a wait period to allow the solution to settle and bubbles to clear. The gas transit time from the polarizer was minimized by diverting approximately 90% of the higher (0.5 SLM) gas flow through the polarizer to a bypass just before the capillary input. For the CEST spectra and temperature dependence data in which concentrated biosensor samples were used (described below), the solutions were bubbled for 25 s with a wait period of 2 s. To reduce the shot noise for the low concentration biosensor samples used in the dilution series experiments (described below), bubbling and wait times of 40 s and 10 s, respectively, were used.
NMR experiments were performed on a 7.05 T Varian UNITY INOVA vertical bore spectrometer equipped with a 26-channel shim set and a dual-tuned ( 1 H/ 129 Xe) radiofrequency (RF) saddle coil (i.d. ¼ 5 mm), and all data were collected with a 25 kHz spectral width and an acquisition time of 0.5 s. Saturation in the CEST pulse sequences was applied with trains of band selective d-SNOB pulses (36) without interpulse delays, which have been previously demonstrated to have high saturation efficiency in xenon biosensor systems (37) . All data were line broadened with an 8 Hz Lorentzian and fitted in the time domain using a nonlinear least-squares regression (MATLAB; MathWorks, Natick, MA), producing signal amplitudes for subsequent analyses.
To compare the Xe@CryA response for the M13-based biosensor relative to the unscaffolded CryA control, CEST spectra were acquired for a 2.3 nM solution of M13-based biosensor and an unscaffolded solution containing an approximately equivalent amount of CryA (2.2 mM) at 293 K. Saturation was applied with a 10 s train of 500 Hz bandwidth d-SNOB pulses (5.64 ms, 59 mT peak field strength; specific absorption rate (SAR) equivalent B 1 of a 35 mT continuous wave pulse) over a frequency offset range of À32 to 390 ppm. Randomized saturation frequency order allowed for retrospective baseline corrections due to slow temporal variations in the hyperpolarized 129 Xe signals were required. Furthermore, the CEST dynamics for these two samples were compared by evaluating contrast versus saturation time at both 293 and 310 K. For these experiments, saturations were applied ''on-resonance'' at the Xe@CryA frequency and ''off-resonance'' at an equal distance from the Xe@water frequency but on the downfield side. The offset frequencies were found to vary modestly due to the association with M13 ( 129 Xe@CryA) as well as with temperature ( 129 Xe@CryA and 129 Xe@water) (see Results section), and the exact frequencies used in these experiments are presented in Table 1 . Saturation durations of up to 20 s were applied using trains of 3 kHz bandwidth d-SNOB pulses (940 ms, 352 mT peak field; SAR equivalent B 1 of a 207 mT continuous wave pulse). Given the differences in saturation times, a variable post-acquisition delay was used to maintain a constant repetition time. Furthermore, it should be noted that undesirable T 1 weightings were already absent from the experiment due to the use refreshed hyperpolarized signals. Plots of the normalized residual signal, equal to (1 À hyperCEST contrast) and expressed as M z,on /M z,off , were generated to illustrate the magnitude of the hyperCEST effect alone.
To investigate the dependence of CEST contrast on the concentration of the M13-based biosensor and to determine a detection threshold, plots of residual signal versus saturation time were generated for a dilution series of the biosensor (2.3 nM, 230 pM, 23 pM, 2.3 pM) at 310 K. The NMR acquisition parameters were identical to those described above for the temperature experiments. Finally, a 230 fM M13-based biosensor solution was evaluated as the lower limit concentration using a single saturation duration of 20 s, and the on-resonance and off-resonance data were analyzed with groupwise and paired (one-tailed) Student's t-tests.
Preliminary experiments using unmodified M13 were used to confirm the absence of exchangeable signals in the 129 Xe CEST spectrum due to the phage itself. Additionally, experiments in solvent alone were used to confirm the absence of baseline asymmetries in the 129 Xe@water signal due to the application of 500 Hz and 3 kHz bandwidth d-SNOB pulse trains (peak B 1 and train durations matched to those used in the respective agent experiments) at the on-resonance and off-resonance frequencies (e.g., >10 kHz from the Xe@water frequency).
RESULTS
The full CEST spectra showed Xe@water signal loss arising from saturation at the 129 Xe@CryA frequency for both the M13-based biosensor and the unscaffolded CryA samples (Fig. 4) . Despite a 2.4 ppm downfield shift and broadness in the 129 Xe@CryA response of the M13-based biosensor compared to that of the unscaffolded CryA (full width at half minimum of 37.6 ppm versus 13.2 ppm; this observation was expected due to the slower tumbling of the supramolecular phage structure), the maximum contrast for two curves was in good agreement (17% and 19%, respectively). Similarly, the saturation time curves at both 293 and 310 K showed comparable contrast for the M13-based biosensor and the unscaffolded CryA (Fig. 5) . As expected, contrast was generated more rapidly at the elevated temperature due to the faster chemical exchange dynamics (e.g., residual signal after 5 s of saturation was 90% and 42% for 293 K and 310 K, respectively). The chemical shifts of 129 Xe@CryA and 129 Xe@water where shifted downfield 2.8 ppm and 0.4 ppm, respectively, when heating the samples from 293 to 310 K.
For all four concentrations of M13-based biosensor used in the dilution series, CEST contrast was clearly visible in the saturation time curves (Fig. 6) , and the decrease in residual signal for each concentration was accurately represented by an exponential decay with saturation time. For these very dilute solutions, the CEST contrast for a given saturation time decreased roughly logarithmically with decreasing M13-based biosensor concentration (Fig. 6, inset) .
Impressively, when a 230 fM M13-based biosensor solution was evaluated, statistically significant contrast was demonstrated. Despite the presence of an outlying on-resonance data point (greater than 3 standard deviations from the group mean; Fig. 7 , right side of dashed line) for the 230 fM M13-based biosensor sample, a mean contrast of 3.7% was measured (P < 0.01 for groupwise and paired t-tests). Excluding the outlying point resulted in a mean contrast of 4.8%.
DISCUSSION AND CONCLUSIONS
This work shows that the filamentous bacteriophage M13 is an effective supramolecular scaffold for multivalent CryA assembly, resulting in a concentration (a, b, c, inset) .
previous reports using continuous wave-based saturations (13) highlights the utility of using d-SNOB trains with higher B 1 strengths for saturating exchanging solvated xenon signals (37) . Modest decreases in the perCryA sensitivity were observed with respect to a similar hyperCEST study using d-SNOB based saturation (27) , which may be due to enhanced xenon binding or exchange dynamics associated with the viral capsids used in that study, or due to possible differences in the experimental conditions-namely the 129 Xe polarization level. We hypothesize that the sensitivity gain may arise from semicoherent inversions of the slowly exchanging xenon spins [t Xe@CryA is approximately 6 ms at 310 K (38)] when using short strong d-SNOB pulses, thus increasing the dynamic range of the altered M z being passed back to the bulk Xe@water pool. Another possible mechanism for the increased per-CryA sensitivity may be solubility-driven conformational changes to CryA when bound to the phage that enhance their accessibility for xenon binding (39) , although this explanation would need to be rectified with the similar hyperCEST responses observed for the unscaffolded and phagebound versions of CryA.
When considering SAR constraints for in vivo applications of 129 Xe-based biosensors, it is favorable to note that due to the low gyromagnetic ratio of 129 Xe relative to 1 H, the peak B 1 field strengths reported must be divided by 3.62 when comparing to SAR equivalents of saturations applied at 1 H carrier frequencies for experiments such as PARACEST and magnetization transfer (i.e., SAR 1 w 1 2 , w 0 2 ). Furthermore, some preliminary results suggest that lower duty cycle d-SNOB saturation trains using interpulse delays may allow for much lower SAR envelopes while realizing only modest reductions in CEST contrast (37) .
The dramatic sensitivity demonstrated by the M13-based 129 Xe biosensors make them an advantageous choice for further development toward targeted molecular MRI applications. Continuing work will be focused on investigating the utility and biocompatibility of antibody-targeted versions of the M13-based biosensor for cellular recognition applications. 
APPENDIX A-CHEMICAL SYNTHESIS AND CHARACTERIZATION
General Synthesis
All chemical reagents were of analytical grade, obtained from commercial suppliers, and used without further purification unless otherwise noted. Organic extracts were dried over MgSO 4 and solvents were removed with a rotary evaporator at reduced pressure. Flash chromatography was performed using Silicycle Siliaflash P60 40-63 Å 230-400 mesh silica gel. NMR spectra were acquired using a Bruker AV-600, AV-500, AVQ-400, or AVB-400 spectrometer.
RP-HPLC
Peptide constructs were purified by RP-HPLC using a Rainin Instruments Dynamax SD-200 system equipped with a Varian UV-Vis detector (model 345) and a Microsorb C18 analytical column (4.6 Â 250 mm) at a flow rate of 1 mL/min, a semipreparative column (10 Â 250 mm) at a flow rate of 4 mL/min, or a preparative column Xe@water frequency (off-resonance). An outlying on-resonance data point is shown by the dashed line. Both groupwise and paired Student's t-tests showed significant contrast (4.8%, or 3.7% with inclusion of the outlier) between the data sets corresponding to the two saturation frequencies (P < 0.01). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
To a stirred solution of N-Boc-aminooxyacetic acid (500 mg, 2.62 mmol) in dichloromethane (30 mL) cooled on an ice bath were added N-hydroxysuccinimide (332 mg, 2.88 mmol) and N,N 0 -dicyclohexylcarbodiimide (594 mg, 2.88 mmol). The solution was stirred for 5 min after which it was removed from the ice bath and stirred at room temperature for 45 min. The reaction was quenched with addition of dichloromethane, filtered through a pad of Celite, and the filtrate was washed with sat. NaHCO 3 (2 Â 40 mL). The organic phase was dried over MgSO 4 and concentrated under vacuum. The white solid was used as is. 1 
Fmoc-Lys[Boc-aminooxyacetyl]AOH (2)
To a stirred solution of the ester 1 (700 mg, 2.43 mmol) and the TFA salt of Fmoc-Lysine (1.24 g, 2.67 mmol) in dry methylene chloride (30 mL) was added N,N-diisopropylethylamine (1.59 mL, 9.17 mmol). The solution was stirred at room temperature for 11 h. The reaction was quenched with addition of dichloromethane and washed with sat. NH 4 Cl (1 Â 40 mL). The aqueous phase was extracted with dichloromethane (3 Â 20 mL), then the organic phases were combined, dried over MgSO 4 , and concentrated under vacuum. Purification by silica gel chromatography using 1:4 ethyl acetate:hexanes with 1% acetic acid gave the desired aminooxy functionalized amino acid as an offwhite residue. Resolving the residue in dichloromethane and adding it dropwise to a solution of hexanes precipitated the product as a white solid (757 mg, 58% þ .
Aminooxy-Functionalized CryA-Peptide (CryAAONH 2 )
The aminooxy-functionalized CryA-peptide was synthesized in four parts. First, a water solubilizing tetraglutamic acid peptide, Glu-Glu-Glu-Glu (EEEE-resin), was prepared on Wang resin (1.2 mmol/g, 100-200 mesh) using standard Fmoc solid-phase peptide synthesis with N aFmoc protected amino acids, N,N-diisopropylethylamine, and 1-hydroxybenzotriazole (HOBT)/O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) ester activation in N,N-dimethylformamide. A 5-fold excess of amino acid was used for the coupling steps, which involved gentle rotation for 3 h. Fmoc removal was achieved with 20% piperidine in N,N-dimethylformamide (2 Â 10 min). Next, the aminooxy functionality was installed by coupling 2 following the same solid-phase peptide synthesis conditions above, except that the coupling was allowed to proceed with gentle rotation for 5 h. Subsequently, a linker was installed using Fmoc-6-aminohexanoic acid and the same solid-phase peptide synthesis conditions as above. Finally, the peptide was capped at the N-terminus using a 2.5-fold excess of the Cryptophane-A monoacid cage (monoacid CryA supplied by Kang Zhao, Tianjin University, China) using the same solid-phase peptide synthesis conditions as above, except that the coupling was allowed to proceed with gentle rotation for 12 h. The product was cleaved using a cocktail of trifluoroacetic acid:water:triisopropylsilane (95:2.5:2.5) for 2.5 h and then precipitated in methyl tert-butyl ether. The crude product was purified by RP-HPLC using a C18 column with a gradient from 40 to 60% buffer B over 30 min. A 8 mM stock solution of the aminooxy-functionalized CryA-peptide construct was prepared by dissolving the purified solid in Dulbecco's phosphate-buffered saline and adjusting the pH with sodium hydroxide until the solution became clear. 
